Table 1.
Demographic and disease characteristics of patients with RET fusion-positive NSCLC and intracranial disease.
| Characteristics | All patients with RET fusion-positive NSCLC and intracranial metastases (N = 80) |
|---|---|
| Age | |
| Median (range), years | 62 (36–86) |
| Sex, n (%) | |
| Female | 54 (68) |
| Male | 26 (33) |
| Race, n (%) | |
| White | 44 (55) |
| Asian | 31 (39) |
| Black or African American | 2 (3) |
| Other | 2 (3) |
| Unknown | 1 (1) |
| Smoking history, n (%) | |
| Never | 63 (79) |
| Former | 16 (20) |
| Current | 1 (1) |
| ECOG performance status, n (%) | |
| 0 | 22 (28) |
| 1 | 54 (68) |
| 2 | 4 (5) |
| NSCLC histologic subtype, n (%) | |
| Adenocarcinoma | 69 (86) |
| Large cell neuroendocrine carcinoma | 2 (3) |
| NSCLC-NOS | 8 (10) |
| Other | 1 (1) |
| RET fusion partner, n (%) | |
| KIF5B | 56 (70) |
| CCDC6 | 11 (14) |
| NCOA4 | 2 (3) |
| Other | 4 (5) |
| Unknowna | 7 (9) |
| Prior therapy, n (%) | |
| Number of prior systemic regimens | |
| 0 | 7 (9) |
| 1–2 | 43 (54) |
| 3 or more | 30 (38) |
| Median prior systemic regimen (range) | 2 (0–10) |
| Type of prior systemic therapyb | |
| Platinum chemotherapy | 63 (79) |
| Anti PD-1/PD-L1 antibody | 43 (54) |
| Multikinase inhibitor | 33 (41) |
| Taxane chemotherapy | 25 (31) |
| Other systemic therapy | 31 (39) |
| Intracranial radiotherapyb | 45 (56) |
| Whole brain radiation therapy | 11 (14) |
| Stereotactic radiosurgery | 36 (45) |
| Intracranial radiotherapy timing | |
| Completed >2 months prior to selpercatinib treatment | 33 (41) |
| Intracranial surgery | 7 (9) |
aRET fusion identified by molecular analysis with an assay unable to identify the fusion partner (e.g. FISH).
bPatients may be counted in more than one row.